Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL989414 | 1.00 | TP53 (0.69) | TP53TSHREGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL746753 | 1.00 | TP53 (0.69) | TP53TSHREGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8460431 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL16681176 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL14157638 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL14157640 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL16681178 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL8460437 | 0.97 | TP53 (0.65) | TP53TSHREGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL7489586 | 0.87 | TSHR (0.64) | TP53TSHREGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL27659186 | 0.87 | TSHR (0.64) | TP53TSHREGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163687-B2 | Mixture of amine oxide, glycerol ether solvent, chelate compound and cationic polymers; free of anionic surfactants | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-24 | — | — | US | claimed |
| US-20080255018-A1 | Liquid hard surfaces cleaning compositions | THE PROCTER & GAMBLE COMPANY | 2008-10-16 | — | — | US | claimed |
| EP-1927651-A1 | Liquid hard surface cleaning compositions | The Procter and Gamble Company (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2008059453-A1 | LIQUID HARD SURFACES CLEANING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-22 | — | — | WO | claimed |
| US-20070072812-A1 | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones | MICROBIA, INC. (US) | 2007-03-29 | — | — | US | claimed |
| EP-1660456-A2 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | Microbia Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021495-A2 | QUATERNARY SALT DERIVATIVES OF 1,4-DIPHENYLAZETIDIN-2-ONES | MICROBIA INC. (US) | 2005-03-10 | — | — | WO | claimed |
| WO-1999060086-A1 | LIQUID ACIDIC HARD SURFACE CLEANING COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0957156-A1 | Liquid acidic hard surface cleaning composition | THE PROCTER & GAMBLE COMPANY (US) | 1999-11-17 | — | — | EP | claimed |
| EP-3851108-B1 | BORATE-BASED DRUG AND USE THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20220324908-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | CYTOGEL PHARMA, LLC | 2022-10-13 | — | — | US | disclosed |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3851108-A1 | BORATE-BASED DRUG AND USE THEREOF | Chengdu Origin Biotechnology Limited Company (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339628-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | CYTOGEL PHARMA, LLC | 2020-10-29 | — | — | US | disclosed |
| EP-0326981-A2 | 4-Oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives, their preparation, medicaments containing them and their preparation | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1989-08-09 | — | — | EP | disclosed |
| US-4761417-A | INOTROPIC AGENTS | MAROKO, ANDREW | 1988-08-02 | — | — | US | disclosed |
| EP-0241618-A2 | Phenyl ethanol amine derivative for use as an oncolytic medicament | ELI LILLY AND COMPANY (US) | 1987-10-21 | — | — | EP | disclosed |
| EP-0108147-A4 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-09-13 | — | — | EP | disclosed |
| EP-0108147-A1 | Use of a protoberberine alkaloid and composition containing same. | MAROKO PETER R | 1984-05-16 | — | — | EP | disclosed |
| WO-1983003970-A1 | COMPOUNDS, COMPOSITIONS AND METHOD OF TREATMENT FOR IMPROVING CIRCULATORY PERFORMANCE | MAROKO PETER R | 1983-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339628-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | OPRM1, OPRL1, OPRK1 | TP53 3194/4885TSHR 127/4885EGLN1 4880/4885 |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | PSMB11, PSMB1, PSMB3 | TP53 1800/4885TSHR 967/4885EGLN1 1916/4885 |
| US-20070072812-A1 | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones | PCSK9, SLC10A1, QDPR | TP53 2699/4885TSHR 4269/4885EGLN1 1247/4885 |
| US-20220324908-A1 | ADVANTAGEOUS SALTS OF MU-OPIATE RECEPTOR PEPTIDES | OPRM1, OPRL1, OPRK1 | TP53 3194/4885TSHR 127/4885EGLN1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.